A Study of CD137 Agonist ADG106 Administered Intravenously in Patients With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
Phase of Trial: Phase I
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs ADG 106 (Primary)
- Indications Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Adagene
- 30 Oct 2019 Results (data cut off: 11 July 2019) presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019
- 26 Oct 2019 According to Adagene media release, data from this trial will be presented at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston, Massachusetts on Sunday, Oct. 27th 2019.
- 25 Sep 2019 Planned number of patients changed from 33 to 49.